Zusammenfassung
Bei elf Probanden und 39 Patienten, die sich einer transurethralen Resektion der Prostata oder eines Blasentumors unterziehen mußten, wurden Enoxacinkonzentrationen in der Samenflüssigkeit (Probanden), im Prostatasekret (Probanden, Patienten) und im Prostataadenomgewebe (Patienten) nach oraler Gabe von 400 mg bzw. intravenöser Infusion (60 min) von 428 mg Enoxacin gemessen. Gleichzeitig wurde 2,534 g Ioxitalaminsäure intravenös verabreicht, um mögliche Urinkontaminationen zu identifizieren. Die Enoxacinkonzentrationen in der Samenflüssigkeit nach 2–4 h und im Prostataadenomgewebe nach 1–4 h und nach 14–16 h waren mehr als doppelt so hoch wie die Plasmakonzentrationen. Die Prostatasekretkonzentrationen lagen dagegen nach 1–4 h bei etwa der Hälfte der Plasmakonzentrationen. Nach intravenöser Infusion bei 14 Patienten wurden in Intervallen bis zu 24 h venöse Blutproben entnommen, die Plasmakonzentrationen bestimmt und die pharmakokinetischen Parameter berechnet. Die mittlere maximale Plasmakonzentration von Enoxacin lag am Ende der Infusion bei 6,9 mg/l und sank auf 0,5 mg/l nach 12 h. Eine terminale Halbwertszeit von 6,65 h wurde entsprechend einem offenen Zwei-Kompartiment-Modell errechnet.
Summary
In eleven volunteers and 39 patients undergoing transurethral resection of the prostate or bladder tumor, concentrations of enoxacin were measured in seminal fluid (volunteers), in prostatic fluid (volunteers, patients) and in prostatic adenoma tissue (patients) after oral (400 mg) administration and intravenous (428 mg) infusion (60 min) of enoxacin. Simultaneously 2.534 g of ioxitalamic acid was i.v. injected to identify possible urinary contamination. The concentrations of enoxacin in seminal fluid after 2–4 h and in prostatic tissue after about 1–4 h and 14–16 h exceeded plasma concentrations more than two-fold. The concentrations in prostatic fluid after 1–4 h were about half the plasma concentrations. Venous blood samples were taken after intravenous infusion at intervals of up to 24 h in a total of 14 patients. The mean plasma concentration of enoxacin decreased from its maximum of 6.9 mg/l at the end of infusion to 0.5 mg/l at 12 h after administration. A terminal half life of 6.65 h was calculated according to an open two-compartment model.
Literatur
Chin, N. X., Neu, H. C. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new-β-lactams, aminoglycosides, and trimethoprim. Antimicrob. Agents Chemother. 24 (1983) 754–763.
Nakamura, S., Mimami, A., Katac, H., Inoue, S., Yamagashi, J., Takase, Y., Shimizu, M. In vitro antibacterial properties of AT-2266, a new pyridone-carboxylic acid. Antimicrob. Agents Chemother. 23 (1983) 641–648.
Wise, R., Andrews, J. M., Danks, G. In vitro activity of enoxacin (CI-919), a new quinolone derivative, compared with that of other antimicrobial agents. J. Antimicrob. Chemother. 13 (1984) 237–244.
Wise, R., Lockley, R., Dent, J., Webberly, M. Pharmacokinetics and tissue penetration of enoxacin. Antimicrob. Agents Chemother. 26 (1984) 17–19.
Adhami, Z., Wise, R., Weston, D., Crump, B. The pharmacokinetics and tissue penetration of norfloxacin. J. Antimicrob. Chemother. 13 (1983) 87–92.
Crump, B., Wise, R., Dent, J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob. Agents Chemother. 24 (1983) 784–786.
Naber, K. G., Sörgel, F., Kees, F., Schumacher, H., Metz, R., Grobecker, H. In vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. J. Antimicrob. Chemother. 22, Suppl. D (1988) 199–207.
Miyata, K., Furukawa, M., Okimune, M., Ishido, N., Akazawa, N., Kumon, H., Ohmori, H., Kondo, A., Nanba, K. Fundamental and clinical studies on AT-2266 in the urological field. Chemotherapy (Tokyo) 32 Suppl. 3 (1984) 796–810.
Suzuki, K., Tamai, H., Naide, Y., Fujita, T., Ogawa, T., Yanagioka, M. Diffusion of AT-2266, a new oral synthetic antimicrobial agent, into human prostatic fluid and clinical investigations in urinary tract infections. Chemotherapy (Tokyo) 32 Suppl. 3 (1984) 724–740.
Madsen, P. O., Dørflinger, T. Enoxacin concentrations in prostatic tissue, prostatic secretions, interstitial fluid and other tissues: an experimental study in dogs. Journal of International Biomedical Information and Data 6 (1985) 41–44.
Stamey, T. A., Meares, E. M., Winningham, D. G. Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid. J. Urol. 103 (1970) 187–194.
Madsen, P. O., Dørflinger, T., Larsen, E. H., Gasser, T. C. Pharmacokinetics of antibacterial agents used for treatment of bacterial prostatitis. p 17–20 In:W. Weidner, H. Brunner, W. Krause, C. F. Rothauge (eds.): Therapy of prostatitis. W. Zuckschwerdt, Munich, Bern, Vienna, San Francisco 1986.
Winningham, D. G., Nemoy, N. J., Stamey, T. A. Diffusion of antibiotics from plasma into prostatic fluid. Nature 219 (1968) 139–143.
Blacklock, N. J., Beavis, J. P. The response of prostatic fluid pH in inflammation. Br. J. Urol. 46 (1974) 537–542.
Pfau, A., Perlberg, S., Shapira, A. The pH of the prostatic fluid in health and disease: Implications of treatment in chronic bacterial prostatitis. J. Urol. 119 (1978) 384–387.
Yasumoto, R., Kobayakwa, H., Asakawa, M. Enoxacin concentration in human prostatic tissue. Hinyokika Kiyo 32 (1983) 1471–1473.
Desai, K. M., Abrams, P. H., White, L. O. A double-blind comparative trial of short-term orally administered enoxacin in the prevention of urinary infection after elective transurethral prostatectomy: a clinical and pharmacokinetic study. J. Urol. 139 (1988) 1232–1234.
Ranniko, S., Malmborg, A. S. Enoxacin concentration in human prostatic tissue after oral administration. J. Antimicrob. Chemother. 17 (1986) 123.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Naber, K.G., Schumacher, H., Sigl, G. et al. Enoxacin-Konzentrationen in der Samenflüssigkeit, im Prostatasekret und im Prostataadenomgewebe nach oraler Gabe oder intravenöser Infusion. Infection 17 (Suppl 1), S30–S36 (1989). https://doi.org/10.1007/BF01643634
Issue Date:
DOI: https://doi.org/10.1007/BF01643634